Overview of Acebrophylline Capsules:

UNOBRO-OD Sustained Release Tablets contains Acebrophylline which has an advantage of once daily administration. It has inherent benefits in terms of patient compliance. Acebrophylline was found to be superior to theophylline in efficacy and tolerability in patients with mild bronchial asthma and mild persistent asthma.



Acebrophylline belong to the class of xanthine derivative and a bronchodilator.

UNOBRO-OD Sustained Release Tablets can be used for the treatment of following conditions:

  • Bronchial asthma
  • COPD (Chronic Obstructive Pulmonary Disease).

One UNOBRO-OD Tablet once daily.

Acebrophylline is an anti-inflammatory and airway mucus regulator. It contains ambroxol and theophylline-7 acetic acid, the former facilitates the biosynthesis of pulmonary surfactant while later raises blood levels of ambroxol thereby stimulating surfactant production. The improvement in ciliary clearance results by reduction in the viscosity and adhesivity of mucus.